HeartBeam, Inc. (BEAT)

HeartBeam's stock price has decreased significantly, trading at $0.8901 as of May 9, 2026, down 62.8% since the beginning of the year. Key events include FDA clearance of its 12-lead ECG synthesis software in December 2025, first patient enrollments in the ALIGN-ACS pilot study in March 2026, reporting fourth quarter and full year 2025 results in March 2026, closing an underwritten public offering of 12,500,000 shares in April 2026, and announcing a commercial agreement with Atelier Health in May 2026.

The provided search results do not contain specific information regarding the demand seasonality for HeartBeam, Inc.'s products and services. Demand is likely driven more by regulatory approvals, clinical adoption, and market penetration rather than traditional seasonal consumer patterns. Its target market suggests a more consistent demand based on medical necessity and physician recommendations, rather than seasonal fluctuations.

HeartBeam, Inc. is a medical technology company focused on transforming cardiac care through remote patient monitoring solutions. The company develops and commercializes a medical technology platform for remote cardiac monitoring, including an FDA-cleared device that collects heart signals and synthesizes a 12-lead ECG for arrhythmia assessment. HeartBeam also has a prototype of an on-demand 12-lead ECG patch in development and partners with HeartNexus for cardiologist reader services.

HeartBeam, Inc. is headquartered in Santa Clara, California. The company has expanded its commercial footprint across four key U.S. launch markets: New York metro, Dallas, South Florida, and Southern California, primarily through agreements with concierge and preventive cardiology practices.

HeartBeam's brand reputation has been shaped by regulatory achievements and strategic partnerships, positioning it as an innovator in remote cardiac monitoring. Positive events include FDA clearances, partnerships with HeartNexus and Mount Sinai, commercial agreements, and a strong patent portfolio. However, the company is pre-revenue, dependent on clinical trials and FDA clearance, and lacks brand recognition compared to established competitors.

HeartBeam, Inc. has 39 institutional owners and shareholders holding a total of 4,498,778 shares. Institutional investors own 11.11% of the company, while HeartBeam insiders own 17.25%, and retail investors hold 71.64%. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. Major individual owners include Mark E. Strome, Branislav Vajdic, Willem Elfrink, and Richard Ferrari. In the past three months, HeartBeam insiders have bought a net of $895,000.00 in company stock.